Immune cell cocktail takes on Platinum-Resistant ovarian cancer
NCT ID NCT06710288
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new approach for people with platinum-resistant high-grade ovarian cancer, a type that no longer responds to standard chemotherapy. Up to 20 participants will receive their own immune cells (M-CENK) that have been trained to fight cancer, along with an immune booster (N-803) and the chemotherapy drug gemcitabine. The goal is to see if this combination can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
M-CENK (memory cytokine enriched natural killer cells), N-803 (IL-15 superagonist), and gemcitabine
What this could lead to
If it works, this could offer a new treatment option for people with ovarian cancer that no longer responds to platinum-based chemotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination therapy may cause side effects and may not shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Chan Soon-Shiong Institute for Medicine
RECRUITINGEl Segundo, California, 90245, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hoag
RECRUITINGNewport Beach, California, 92663, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact